Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01575171 · ClinicalTrials.gov registry record
Using Nudges to Implement Comparative Effectiveness
A clinical trial of Hypercholesterolemia, sponsored by NYU Langone Health.
- Completed
- Registry status
- 19
- Enrollment target
- 1
- Study location
NCT01575171: Completed study of Hypercholesterolemia, sponsored by NYU Langone Health.
NCT01575171 is a study of Hypercholesterolemia that has completed, run by NYU Langone Health. The registered enrollment target is 19 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01575171, a study of Hypercholesterolemia, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
Behavioral economics represents a powerful, albeit underutilized tool to influence provider and systems behavior in a large-scale, meaningful, and sustainable way. The investigators propose to use a sophisticated electronic health record (EHR) system to change the default choice for physicians to the choice most supported by clinical practice guidelines (CPG). Multiple guidelines exist describing best practices for effective interventions, yet a large gap persists between actual and optimal guideline compliance. The proposed study will examine the comparative effectiveness of an opt-out medication management protocol relative to usual care for patients not at goal, using national guidelines for cholesterol management implemented in large multispecialty private practices that use an Electronic Health Record system. Specific Aim: To determine the effectiveness of altering the default option in an EHR in prescribing statins to selected patients using clinical decision support. Hypotheses: Compared to usual care, a CPG-concordant intervention designed using behavioral economics principles will significantly improve the proportion of patients who are prescribed statins.
Primary Outcome
A "Nudge" or opt-out default option is implemented in the electronic health record system based on national clinical guidelines. We plan to measure if the Nudge is accepted or rejected by doctors.
Conditions Studied
Interventions
- BEHAVIORAL Nudge
Study Locations (1)
New York
- Murray Hill Medical Group - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-09 |
| Est. Completion | 2015-05 |
What the finished NCT01575171 record still lists
NCT01575171 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which Nudge is the first listed.
NCT01575171 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01575171 about?
NCT01575171 is a clinical study titled "Using Nudges to Implement Comparative Effectiveness". Behavioral economics represents a powerful, albeit underutilized tool to influence provider and systems behavior in a large-scale, meaningful, and sustainable way. The investigators propose to use a sophisticated electronic health record (EHR) system to change the default choice for physicians to th...
What is the current status of trial NCT01575171?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2010-09. Estimated completion is 2015-05.
What conditions does trial NCT01575171 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT01575171?
The interventions under investigation include: Nudge (BEHAVIORAL).
Who is sponsoring clinical trial NCT01575171?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01575171 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01575171's enrollment target sits among peer trials
19 60th of 62 higher than 3 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacokinetics of Butyrate Tablet BKR-017
RECRUITING
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
RECRUITING · NA
-
Pharmacogenomic Informed Statin Prescribing
RECRUITING · NA
-
Causes and Natural History of Dyslipidemias
RECRUITING
-
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia